Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133141 | 1.00 | NAALAD2 (0.39) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL1133246 | 1.00 | NAALAD2 (0.39) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL3019562 | 0.81 | MAPT (0.34) | NAALAD2SMN1; SMN2FPR2ALDH1A1KDM4E | |
| SCHEMBL13209005 | 0.80 | TSHR (0.45) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL13209006 | 0.80 | TSHR (0.45) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL13209014 | 0.80 | TSHR (0.45) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL25446061 | 0.80 | NAALAD2 (0.45) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL14879626 | 0.80 | NAALAD2 (0.45) | NAALAD2TSHRSMN1; SMN2FPR2ALDH1A1 | |
| SCHEMBL10575333 | 0.79 | FPR2 (0.49) | NAALAD2TSHRSMN1; SMN2FPR2MAPT | |
| SCHEMBL10575336 | 0.79 | FPR2 (0.49) | NAALAD2TSHRSMN1; SMN2FPR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993800-B2 | Process for producing optically active α-methylcysteine derivative | KANEKA CORPORATION (JP) | 2015-03-31 | — | — | US | claimed |
| EP-2287152-B1 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORP (JP) | 2015-01-14 | — | — | EP | claimed |
| US-20130261331-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORP (JP) | 2013-10-03 | — | — | US | claimed |
| EP-2287152-A2 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2011-02-23 | — | — | EP | claimed |
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-08-05 | — | — | US | claimed |
| US-20060172393-A1 | Process for producing optically active alpha -methylcysteine derivative | KANEKA CORPORATION | 2006-08-03 | — | — | US | claimed |
| US-20060105435-A1 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2006-05-18 | — | — | US | claimed |
| EP-1584690-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE a-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-10-12 | — | — | EP | claimed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | claimed |
| US-10071958-B2 | Method for producing alpha-substituted cysteine or salt thereof or synthetic intermediate of alpha-substituted cysteine | API CORPORATION (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180251424-A1 | Method for Producing Alpha-substituted Cysteine or Salt Thereof or Synthetic Intermediate of Alpha-substituted Cysteine | API CORPORATION (JP) | 2018-09-06 | — | — | US | disclosed |
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | API CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
| US-8993800-B2 | Process for producing optically active α-methylcysteine derivative | KANEKA CORPORATION (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993800-B2 | Process for producing optically active α-methylcysteine derivative | KANEKA CORPORATION (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-1584690-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE a-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-10-12 | — | — | EP | disclosed |
| EP-1584690-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE a-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-10-12 | — | — | EP | disclosed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004063385-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE α-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003106689-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE α-METHYLCYSTEINE DERIVATIVE | 鐘淵化学工業株式会社 (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | MGMT, GSTA1, CBS | NAALAD2 109/4885TSHR 1898/4885SMN1; SMN2 4462/4885 |
| US-10071958-B2 | Method for producing alpha-substituted cysteine or salt thereof or synthetic intermediate of alpha-substituted cysteine | MGMT, GSTA1, CBS | NAALAD2 198/4885TSHR 1989/4885SMN1; SMN2 4354/4885 |
| US-20180251424-A1 | Method for Producing Alpha-substituted Cysteine or Salt Thereof or Synthetic Intermediate of Alpha-substituted Cysteine | MGMT, GSTA1, CBS | NAALAD2 198/4885TSHR 1989/4885SMN1; SMN2 4354/4885 |
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | AHCY, CTH, BHMT | NAALAD2 17/4885TSHR 4129/4885SMN1; SMN2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.